Microbix Biosystems Inc
TSX:MBX

Watchlist Manager
Microbix Biosystems Inc Logo
Microbix Biosystems Inc
TSX:MBX
Watchlist
Price: 0.215 CAD 2.38% Market Closed
Market Cap: 30m CAD

Microbix Biosystems Inc
Free Cash Flow

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Microbix Biosystems Inc
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
Microbix Biosystems Inc
TSX:MBX
Free Cash Flow
-CA$270.8k
CAGR 3-Years
N/A
CAGR 5-Years
-9%
CAGR 10-Years
26%
Theratechnologies Inc
TSX:TH
Free Cash Flow
-$3.1m
CAGR 3-Years
40%
CAGR 5-Years
10%
CAGR 10-Years
-23%
Repare Therapeutics Inc
NASDAQ:RPTX
Free Cash Flow
-$70.1m
CAGR 3-Years
N/A
CAGR 5-Years
-80%
CAGR 10-Years
N/A
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Free Cash Flow
$119.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
X
Xenon Pharmaceuticals Inc
NASDAQ:XENE
Free Cash Flow
-$253.3m
CAGR 3-Years
-42%
CAGR 5-Years
-70%
CAGR 10-Years
-31%
Spectral Medical Inc
TSX:EDT
Free Cash Flow
-CA$9.3m
CAGR 3-Years
2%
CAGR 5-Years
-80%
CAGR 10-Years
0%
No Stocks Found

Microbix Biosystems Inc
Glance View

Market Cap
30.2m CAD
Industry
Biotechnology

Microbix Biosystems, Inc. engages in developing and commercializing proprietary biological and technology solutions for human health and wellbeing. The company is headquartered in Mississauga, Ontario. The firm manufactures a range of biological materials for the diagnostics industry, notably antigens (Antigen business) used in immunoassays and its quality assessment and proficiency testing controls (QAPs business). The firm operates in two segments: the development, manufacturing, and sales of antigens as materials for the medical diagnostic industry or as quality assessment products (as finished products) and viral transport medium (VTM) and the development and commercialization of products or technologies such as Kinlytic and . The Kinlyti urokinase, which is a biologic thrombolytic drug used to treat blood clots. The firm's catalogue of catalogue covers a range of pathogens that are implicated in maternal, pediatric, childhood, respiratory, sexually transmitted and insect-borne diseases. Its QAPs are available in over 30 countries.

MBX Intrinsic Value
0.926 CAD
Undervaluation 77%
Intrinsic Value
Price

See Also

What is Microbix Biosystems Inc's Free Cash Flow?
Free Cash Flow
-270.8k CAD

Based on the financial report for Jun 30, 2025, Microbix Biosystems Inc's Free Cash Flow amounts to -270.8k CAD.

What is Microbix Biosystems Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 10Y
26%

Back to Top